CClinicalTrials.gg
Status unknownNCT03842371Updated Feb 15, 2019

Metabolism of Branched-chain Amino Acids in Monocyte/Macrophage During Sepsis

An observational study in Sepsis Syndrome, sponsored by West China Hospital. Status unknown. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by West China Hospital · Observational

The sponsor has not verified this record recently (last verified Feb 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
90
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The current project was designed to examine the metabolic level of branched-chain amino acids in plasm and monocyte/macrophage, and its role in immune dysfunction during sepsis.

Read the detailed description

In this study, the investigators will collect the peripheral blood of 1,3,7,14 day after diagnose of sepsis. Then, the concentration of branched-chain amino acids(BCAAs) in monocytes and plasma, and the expression of BCAAs metabolic enzymes in monocytes will be determined. Additionally, the inflammatory cytokines, e.g., Interleukin-1β (IL-1β), Tumor necrosis factor-α (TNF-α), Interleukin-10 (IL-10), the chemokines macrophage inflammatory proteins 1α and 1β (MIP-1α and 1β) in the peripheral blood and the phagocytic function of monocytes will also be detected. The current project was designed to examine the metabolic level of branched-chain amino acids in plasm and monocyte/macrophage, and its role in immune dysfunction during sepsis.

02

Conditions studied

03

In context

Sepsis

1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.

This study's planned enrollment of 90 is below the median of 160 across 931 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

West China Hospital is the lead sponsor of 483 studies on the registry; 240 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients who are diagnosed as sepsis, with or without type 2 diabetes.

Inclusion criteria

  • patients diagnosed with sepsis, with or without type 2 diabetes
  • healthy volunteers

Exclusion criteria

Exclusion Criteria:

  • patients with immunodeficient diseases
  • patients who accept glucocorticoid or immunosuppressant
  • patients with an age younger than 18 years
  • patients who cannot provide the informed consent
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • Sepsis with type 2 diabetes

    Sepsis patients with type 2 diabetes

    Other: Metabolic level of BCAAs in monocytes and macrophages

  • Sepsis without type 2 diabetes

    Sepsis patients without type 2 diabetes

    Other: Metabolic level of BCAAs in monocytes and macrophages

  • Volunteers

    Healthy volunteers

    Other: Metabolic level of BCAAs in monocytes and macrophages

Interventions

  • OtherMetabolic level of BCAAs in monocytes and macrophages

    Metabolic level of BCAAs in monocytes and macrophages

06

What researchers measure

Primary outcomes

  1. Intracellular levels of branched-chain amino acids in monocytes

    BCAAs Assay Kit will be used to measure the intracellular levels of BCAAs in monocytes.

    Time frame: up to 14 day after diagnose of sepsis

Secondary outcomes

  1. Plasma levels of branched-chain amino acids

    BCAAs Assay Kit will be used to measure the plasma levels of BCAAs.

    Time frame: 1,3,5,7,10,14 day after diagnose of sepsis

  2. The expression of branched-chain amino acid aminotransferase in monocytes

    The expression of branched-chain amino acid aminotransferase in monocytes will be determined by qPCR and western blot.

    Time frame: 1,3,5,7,10,14 day after diagnose of sepsis

  3. The expression of branched-chain α-ketoacid dehydrogenase in monocytes

    The expression of branched-chain α-ketoacid dehydrogenase in monocytes will be determined by qPCR and western blot.

    Time frame: 1,3,5,7,10,14 day after diagnose of sepsis

  4. The expression of PP2Cm in monocytes

    The expression of mitochondrial-targeted phosphatase, PP2Cm in monocytes will be determined by qPCR and western blot.

    Time frame: 1,3,5,7,10,14 day after diagnose of sepsis

  5. The plasma level of IL-1β

    The plasma level of IL-1β will be determined by ELISA kit.

    Time frame: 1,3,5,7,10,14 day after diagnose of sepsis.

  6. The plasma level of TNF-α

    The plasma level of TNF-α will be determined by ELISA kit.

    Time frame: 1,3,5,7,10,14 day after diagnose of sepsis.

  7. The plasma level of IL-10

    The level of IL-10 will be determined by ELISA kit.

    Time frame: 1,3,5,7,10,14 day after diagnose of sepsis.

  8. The plasma level of chemokine MIP-1α.

    The plasma level of chemokine MIP-1α will be determined by ELISA kit.

    Time frame: 1,3,5,7,10,14 day after diagnose of sepsis.

  9. The plasma level of chemokine MIP-1β.

    The plasma level of chemokine MIP-1β will be determined by ELISA kit.

    Time frame: 1,3,5,7,10,14 day after diagnose of sepsis.

  10. The phagocytic index of monocytes.

    The phagocytic index of monocytes will be determined by a E.coli Phagocytosis Assay Kit.

    Time frame: 1,3,5,7,10,14 day after diagnose of sepsis.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03842371
Lead sponsor
West China Hospital
Responsible party
Chunling Jiang (Clinical Professor, West China Hospital) — Principal investigator
First posted
Feb 15, 2019
Start date
Feb 11, 2019 (estimated)
Primary completion
Dec 30, 2021 (estimated)
Completion
Feb 28, 2022 (estimated)
Last update
Feb 15, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion